(RGNX) Regenxbio - Overview
Stock: Gene Therapy, Retinal Diseases, Muscular Dystrophy, Neurological Disorders
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 116% |
| Relative Tail Risk | -5.35% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.72 |
| Alpha | 11.08 |
| Character TTM | |
|---|---|
| Beta | 1.745 |
| Beta Downside | 0.816 |
| Drawdowns 3y | |
|---|---|
| Max DD | 78.42% |
| CAGR/Max DD | -0.29 |
Description: RGNX Regenxbio December 27, 2025
Regenxbio Inc. (NASDAQ:RGNX) is a clinical-stage biotech focused on delivering functional genes to cells with genetic defects using its proprietary NAV Technology Platform, an adeno-associated virus (AAV) delivery system. The company, founded in 2008 and based in Rockville, MD, also licenses this platform to external partners, generating non-dilutive revenue streams.
Its pipeline includes several late-stage candidates: ABBV-RGX-314 (in partnership with AbbVie) targets wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases; RGX-202 is in a Phase III trial for Duchenne muscular dystrophy; RGX-121 addresses mucopolysaccharidosis type II; and early-stage programs such as RGX-111 (MPS I), RGX-181 (late-infantile neuronal ceroid lipofuscinosis type 2), and RGX-381 (ocular manifestations of CLN2). The AbbVie collaboration expands the retinal program outside the United States and includes upfront and milestone payments estimated at >$100 million, though exact terms are undisclosed.
As of Q2 2025, Regenxbio reported cash and equivalents of roughly $200 million with a monthly burn of about $4 million, giving it ~40 months of runway absent additional financing. The gene-therapy sector is projected to grow at a ~15 % CAGR through 2034, driven by expanding FDA approvals and increasing payer acceptance, but competition from other AAV platforms (e.g., Spark, UniQure) raises execution risk. Investors should monitor Phase III readouts for RGX-202 and any regulatory updates for ABBV-RGX-314, as these outcomes will materially affect valuation assumptions.
For a deeper, data-driven valuation of RGNX, you may find ValueRay’s analyst toolkit worth a look.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -177.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.20 > 0.02 and ΔFCF/TA 15.35 > 1.0 |
| NWC/Revenue: 128.6% < 20% (prev 249.8%; Δ -121.3% < -1%) |
| CFO/TA -0.20 > 3% & CFO -103.3m > Net Income -177.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.7m) vs 12m ago 1.75% < -2% |
| Gross Margin: 49.98% > 18% (prev 0.39%; Δ 4958 % > 0.5%) |
| Asset Turnover: 30.89% > 50% (prev 16.24%; Δ 14.65% > 0%) |
| Interest Coverage Ratio: -3.22 > 6 (EBITDA TTM -120.0m / Interest Expense TTM 42.1m) |
Altman Z'' -8.79
| A: 0.39 (Total Current Assets 332.0m - Total Current Liabilities 124.6m) / Total Assets 525.2m |
| B: -2.02 (Retained Earnings -1.06b / Total Assets 525.2m) |
| C: -0.26 (EBIT TTM -135.8m / Avg Total Assets 522.2m) |
| D: -2.91 (Book Value of Equity -1.06b / Total Liabilities 363.8m) |
| Altman-Z'' Score: -8.79 = D |
Beneish M -2.95
| DSRI: 0.55 (Receivables 26.5m/25.2m, Revenue 161.3m/84.3m) |
| GMI: 0.79 (GM 49.98% / 39.46%) |
| AQI: 1.22 (AQ_t 0.07 / AQ_t-1 0.06) |
| SGI: 1.91 (Revenue 161.3m / 84.3m) |
| TATA: -0.14 (NI -177.9m - CFO -103.3m) / TA 525.2m) |
| Beneish M-Score: -2.95 (Cap -4..+1) = A |
What is the price of RGNX shares?
Over the past week, the price has changed by -22.19%, over one month by -20.56%, over three months by -10.09% and over the past year by +37.85%.
Is RGNX a buy, sell or hold?
- StrongBuy: 6
- Buy: 5
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RGNX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 31 | 187.6% |
| Analysts Target Price | 31 | 187.6% |
| ValueRay Target Price | 9.7 | -10.4% |
RGNX Fundamental Data Overview February 03, 2026
P/B = 3.4961
P/EG = 0.26
Revenue TTM = 161.3m USD
EBIT TTM = -135.8m USD
EBITDA TTM = -120.0m USD
Long Term Debt = 76.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 50.8m USD (from shortTermDebt, last quarter)
Debt = 268.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 209.3m USD (from netDebt column, last quarter)
Enterprise Value = 558.9m USD (565.0m + Debt 268.1m - CCE 274.2m)
Interest Coverage Ratio = -3.22 (Ebit TTM -135.8m / Interest Expense TTM 42.1m)
EV/FCF = -5.26x (Enterprise Value 558.9m / FCF TTM -106.3m)
FCF Yield = -19.02% (FCF TTM -106.3m / Enterprise Value 558.9m)
FCF Margin = -65.88% (FCF TTM -106.3m / Revenue TTM 161.3m)
Net Margin = -110.3% (Net Income TTM -177.9m / Revenue TTM 161.3m)
Gross Margin = 49.98% ((Revenue TTM 161.3m - Cost of Revenue TTM 80.7m) / Revenue TTM)
Gross Margin QoQ = -107.9% (prev 57.33%)
Tobins Q-Ratio = 1.06 (Enterprise Value 558.9m / Total Assets 525.2m)
Interest Expense / Debt = 4.91% (Interest Expense 13.2m / Debt 268.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -107.3m (EBIT -135.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.66 (Total Current Assets 332.0m / Total Current Liabilities 124.6m)
Debt / Equity = 1.66 (Debt 268.1m / totalStockholderEquity, last quarter 161.5m)
Debt / EBITDA = -1.74 (negative EBITDA) (Net Debt 209.3m / EBITDA -120.0m)
Debt / FCF = -1.97 (negative FCF - burning cash) (Net Debt 209.3m / FCF TTM -106.3m)
Total Stockholder Equity = 227.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -34.07% (Net Income -177.9m / Total Assets 525.2m)
RoE = -78.29% (Net Income TTM -177.9m / Total Stockholder Equity 227.2m)
RoCE = -44.70% (EBIT -135.8m / Capital Employed (Equity 227.2m + L.T.Debt 76.5m))
RoIC = -47.20% (negative operating profit) (NOPAT -107.3m / Invested Capital 227.2m)
WACC = 9.62% (E(565.0m)/V(833.1m) * Re(12.35%) + D(268.1m)/V(833.1m) * Rd(4.91%) * (1-Tc(0.21)))
Discount Rate = 12.35% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 8.38%
Fair Price DCF = unknown (Cash Flow -106.3m)
EPS Correlation: 66.75 | EPS CAGR: 102.0% | SUE: 3.14 | # QB: 1
Revenue Correlation: -26.72 | Revenue CAGR: -49.95% | SUE: 0.66 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.39 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=-2.07 | Chg30d=-0.001 | Revisions Net=-1 | Growth EPS=+36.2% | Growth Revenue=+36.5%